| Project/Area Number |
17591280
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Radiation science
|
|---|
| Research Institution | Kyushu University |
|---|
Principal Investigator |
KANEKO Koichiro (2007) Kyushu University, Faculty of Medical sciences, Department of Clinical Radiology, Research associate (80403947)
古賀 博文 (2005-2006) 九州大学, 大学病院, 助手 (90343318)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
SASAKI Masayuki Kyushu University, Department of Health Sciences, Graduate School of Medical Sciences, Professor (40240907)
ABE Koichiro Kyushu University, Faculty of Medical sciences, Department of Clinical radiology, Assistant Professor (00380387)
ISODA Takuro Kyushu University, Faculty of Medical sciences, Department of Clinical radiology, Research associate (90452747)
SHIOYAMA Yoshiyuki Kyushu University, Faculty of Medical sciences, Department of Clinical radiology, Assistant Professor (10323304)
HONDA Hiroshi Kyushu University, Faculty of Medical sciences, Department of Clinical radiology, Professor (90145433)
金子 恒一郎 九州大学, 大学病院, 医員 (80403947)
林 和孝 放射線医学総合研究所, 分子イメージング研究センター, 薬剤師 (00325458)
|
|---|
| Project Period (FY) |
2005 – 2007
|
| Project Status |
Completed (Fiscal Year 2007)
|
| Budget Amount *help |
¥4,060,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥360,000)
Fiscal Year 2007: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2006: ¥1,100,000 (Direct Cost: ¥1,100,000)
Fiscal Year 2005: ¥1,400,000 (Direct Cost: ¥1,400,000)
|
|---|
| Keywords | Diagnostic image / Cancer / Positron emission tomography / Estrogen receptor / Stratification of therapeutic method |
|---|
| Research Abstract |
Title: EFFECTS OF HORMONE THERAPY IN PATIENTS WITH ESTROGEN RECEPTOR-EXPRESSING
TUMORS: A STUDY USING POSITRON EMISSION TOMOGRAPHY
[Summary]
We studied the effects of hormone therapy in patients with estrogenreceptor-expressing tumors using FDG-and FES-based positron emission tomography (PET). In the FDG-PET trials, FDG accumulation did not correlate with estrogen receptor expression, but did correlate with tumor size in the 9 breast cancer patients studied. In the 6 recurrent malignant melanoma patients, FDG accumulation did not correlate with the effects of the DAC-Tam method, which was the chemotherapy protocol combined with the estrogen blocker tamoxifen.
Next, we evaluated the correlation between FES-PET findings and the therapeutic effect in three breast cancer patients. In all three cases, estrogen receptors were expressed in the primary sites and all patients had multiple metastatic sites. In two cases, the FES accumulation was different for each metastatic site; for example, high
… More
FES accumulation was observed in brain metastases, but no accumulation was observed in bone metastases. In one bone metastases patient without FES accumulation, hormone therapy was not effective, and resulted in much more advanced bone metastases after six months. It was suggested that the effects of hormone therapy may differ according to metastatic site, even if estrogen receptors are expressed at the same primary site. In one case with high FES accumulation in all metastatic sites, hormone therapy was effective. After one year, tumor marker ST 439 was almost normalized in this patient. We investigated the correlation between FES-PET findings and FDG-PET findings in two cases of breast cancer.FDG accumulation was observed in all metastatic sites in both patients; however, hormone therapy was effective in the one FES-positive case but not in the other FES-negative case.
In conclusion, it appeared that FES-PET but not FDG-PET may be useful to predict the effects of hormone therapy. Further examinations with larger numbers of patients are required to clarify the role of FES-PET. Less
|
